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Cell-mediated immunityBased on the immunogenicity of domain III from the Envelope protein of dengue virus as well as the proven
protective capacity of the capsid antigen, we have designed a novel domain III-capsid chimeric protein with
the goal of obtaining a molecule potentially able to induce both humoral and cell-mediated immunity (CMI).
After expression of the recombinant gene in Escherichia coli, the domain III moiety retained its antigenicity as
evaluated with anti-dengue sera. In order to explore alternatives for modulating the immunogenicity of the
protein, it was mixed with oligodeoxynucleotides in order to obtain particulated aggregates and then
immunologically evaluated in mice in comparison with non-aggregated controls. Although the humoral
immune response induced by both forms of the protein was equivalent, the aggregated variant resulted in a
much stronger CMI as measured by in vitro IFN-γ secretion and protection experiments, mediated by CD4+
and CD8+ cells. The present work provides additional evidence in support for a crucial role of CMI in
protection against dengue virus and describes a novel vaccine candidate against the disease based on a
recombinant protein that can stimulate both arms of the acquired immune system.
© 2009 Elsevier Inc. All rights reserved.Introduction
Dengue infection is currently one of the most important
arthropod-borne diseases, causing up to 25,000 deaths annually.
The disease is endemic in subtropical and tropical countries in most of
which proper Aedesmosquito vector control is lacking (Gubler, 2002;
Stephenson, 2005). Dengue fever and Dengue hemorrhagic fever are
caused by four serologically and genetically related viruses, termed
dengue (DEN) virus types 1–4, which belong to the genus Flavivirus,
family Flaviviridae (Gubler, 2002).
There are currently no licensed vaccines against this disease.
However, some vaccine programs have focused on developing live
attenuated DEN virus vaccines (Sabchareon et al., 2002, 2004;
Simasathien et al., 2008), which are the most advanced vaccine
candidates against the infection. Although results are promising, viral
interference by competition among serotypes, the associated reacto-
genicity in clinical trials and the administration of several doses have
hampered their clinical development (Bhamarapravati and Sutee
2000; Sabchareon et al., 2002).ll rights reserved.A large number of reports can be found in the literature describing
recombinant protein subunits as vaccine candidates for Dengue
(Simmons et al., 1998; Guzmán et al., 2003; Putnak et al., 2005;
Hermida et al., 2006; Chen et al., 2007; Babu et al., 2008; Valdés et al.,
2009). Many of them use fragments of the Envelope (E) glycoprotein,
which is the major structural protein on the surface of the mature
virion and contains neutralizing epitopes (Rey et al., 1995). Domain III
of the E protein, speciﬁcally, has been proposed to be involved in
receptor recognition (Chen et al., 1996), as supported by several
studies demonstrating that both recombinant domain III proteins and
antibodies generated against domain III of ﬂaviviral E antigens can
inhibit entry to target cells (Crill and Roehrig, 2001; Hung et al., 2004;
Chin et al., 2007). We have previously described the functionality of
fusion proteins containing domain III of the E protein from DEN virus
in terms of their induction of neutralizing antibodies and protection in
mice and monkeys (Hermida et al., 2004a, 2004b, 2006; Bernardo et
al., 2008; Valdés et al., 2009).
Cell-mediated immunity (CMI) has recently been recognized as an
important factor in protection against DEN virus in mice. The ﬁrst
report described the contribution of the CD8+ cells in protection
conferred by mice immunization with the Yellow fever-dengue
chimeric virus (Van der Most et al., 2000). A second recent work
demonstrated the role of the cellular response against DEN virus after
infection with the homologous virus in mice (Gil et al., 2009). In the
Fig. 1. Recombinant expression plasmid pDomIII-Capsid2.
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four CD8+ T cell epitopes from DEN that are immunodominant in this
species enhances viral clearance in the same animal model (Yauch et
al., 2009). On the other hand, in our group partial protective capacity
of a semipuriﬁed fraction of the capsid protein was demonstrated,
expressed in Escherichia coli, in themouse encephalitis model without
the induction of a functional humoral response (Lazo et al., 2007).
Since the available evidence suggests that both the humoral and
cellular arms of the immune response have to be stimulated in order
to develop an effective dengue vaccine, we have designed andFig. 2. Expression, semipuriﬁcation and antigenic characterization of the recombinant domai
Lanes: (1) molecular weight markers; (2) supernatant from disruption of cells transformed
supernatant from disruption. (B) Analysis by SDS-PAGE at 15% of the domain III-capsid s
disruption; (3) fraction not adsorbed to thematrix; (4) fraction eluted with washed buffer; (
at 12.5% of the control proteins and the domain III-capsid protein. Lanes: (1) molecular wei
domain III from DEN-2 virus). (D) Western blot using monoclonal antibody 8H8. Lanes: (1)
protein. (E) Western blot using monoclonal antibody 448 (anti-P64k protein), as isotype conobtained a novel chimeric domain III-capsid protein, containing
antigen fragments potentially inducer of neutralizing antibodies and
CMI, respectively. Themolecule was efﬁciently produced in E. coli, and
could be properly folded and puriﬁed. When presented as a
particulated aggregate, it induces antiviral and neutralizing anti-
bodies, CMI, and confers a signiﬁcant level of protection in mice.
Results
Cloning, expression and semipuriﬁcation of the domain III-capsid protein
The region corresponding to domain III, amino acids 286-426 of
the E protein from DEN-2 virus was ampliﬁed from the viral genome
by RT-PCR and cloned into the expression vector pDC-2 (Lazo et al.,
2007), which already contains the gene codifying for the capsid
protein of DEN-2 virus under the transcriptional control of a T5 phage
promoter inducible by IPTG. The resultant plasmid was named
pDomIII-Capsid2 (Fig. 1). XL1-Blue cells were transformed with the
resultant plasmid and the protein expression was analyzed by SDS-
PAGE. As a result a band of ∼30 kDa, accounting for 10% of total
cellular proteins, was detected and immunoidentiﬁed with an anti-
DEN-2 HMAF (Fig. 2A). The protein was identiﬁed as domain III-n III-capsid protein. (A) Analysis by SDS-PAGE at 15% of the pDomIII-Capsid2 expression.
with the pDomIII-Capsid2 plasmid; (3) Western blot using the anti-DEN-2 HMAF of the
emipuriﬁcation process. Lanes: (1) molecular weight markers; (2) supernatant from
5) fraction eluted with elution buffer; (6) fraction in TE buffer. (C) Analysis by SDS-PAGE
ght markers; (7) capsid protein; (8) domain III-capsid protein; (9) PD5 protein (P64k-
molecular weight markers; (6) domain III-capsid protein; (7) capsid protein; (9) PD5
trol antibody. Lanes: (6) domain III-capsid protein; (7) capsid protein; (9) PD5 protein.
Table 1
Reactivity by ELISA of anti-DEN sera against domain III-capsid or capsid protein.
Speciesa Antibody titers
capsid protein domain III-capsid protein Anti-DEN-2 virusb




GMT – 107,634.7 861,077.9
Monkey b800 3200 6400
b800 1600 6400
b800 3200 6400
GMT – 2539.8 6400
Mouse b10,000 160,000 1,280,000
b10,000 80,000 640,000
b10,000 320,000 1,280,000
GMT – 160,000 1,015,937
a Sera of different species.
b Reactivity against DEN-2 virus of the anti-DEN sera.
Fig. 3. Characterization of aggregated structures of particles of the domain III-capsid
protein. Morphology and size of the aggregated particles were analyzed by electron
microscopy. Samples were negatively stained using uranyl acetate and analyzed by
transmission electron microscopy. (A) Semipuriﬁed domain III-capsid protein in TE
buffer; (B) Semipuriﬁed domain III-capsid protein in TE buffer previously incubated
with DNA oligonucleotides. Black arrows indicate particles corresponding to domain III-
capsid protein. The bar represents 200 nm.
251I. Valdés et al. / Virology 394 (2009) 249–258capsid, which corresponded with the expected size, approximately
17 kDa to the domain III region and 12 kDa to the capsid region. This
protein was expressed in soluble form, according to electrophoretic
analysis of soluble and insoluble fractions obtained after disruption on
a French press of the XL1-Blue cells transformed with the recombi-
nant plasmid.
Based on the theoretical isoelectric point of this molecule, the
protein was further puriﬁed following a process similar to that
previously described for the recombinant capsid protein (López et al.,
2009), using an SP-Sepharose FF column for cation exchange
chromatography. The ﬁnal purity of the obtained preparation was
65% of the total protein (Fig. 2B).
Characterization of the recombinant domain III-capsid protein
The analysis of the semipuriﬁed domain III-capsid protein by SDS-
PAGE showed the lowmolecular weight protein contaminants (Fig. 2C).
The identity of the lower bands present in the semipuriﬁed preparation
was examined by Western blots using the monoclonal antibody 8H8,
which recognizes the native capsid protein from DEN-2 virus (Pupo
Antunez et al., 1997). As shown in Fig. 2D, the bands were reactive with
antibody 8H8, suggesting that they arose as a consequenceof proteolytic
degradation. These bands were not immunoidentiﬁed when an isotype
control antibody was used (Fig. 2E).
The semipuriﬁed preparation was also analyzed by mass spectro-
metry, verifying the identity of the molecule and the correct
formation of the disulphide bond of domain III. Identiﬁed peptides
accounted for 80% coverage of domain III region, ensuring the identity
of the domain III region in the ﬁnal construct (data not shown).
Consistently, the ELISA detecting the recognition of the recombi-
nant protein domain III-capsid against different sources of sera
conﬁrmed the previous statement. Domain III-capsid was successfully
recognized by anti-DEN sera obtained from different species (Table 1)
and this reactivity was not detected for the recombinant capsid
protein alone. It means, the reactivity was mainly directed to the
domain III region, which is exposed on the virion surface, instead of
capsid protein which is naturally enveloped and therefore its
accessibility to conformational antibodies is dramatically diminished
(Kuhn et al., 2002; Mukhopadhyay et al., 2003).
In vitro assembly process
In order to obtain particulated assemblies of the recombinant
domain III-capsid protein, the partially puriﬁed preparation was
incubated with a mixture of 50-base-long DNA oligonucleotides at a
3:1 protein:oligonucleotide molar ratio basically according to the
procedure described by López et al. (2009), verifying the obtention ofaggregates by electron microscopy. As shown in Fig. 3, aggregates,
including particles, were observed only in the sample corresponding
to the assembly reaction. The diameter of the particles ranged from 20
to 22 nm.
Immunological evaluation of different species of the recombinant
domain III-capsid protein
The immunogenicity of the domain III-capsid protein in non-
aggregated and aggregated forms was evaluated in mice using
aluminum hydroxide as adjuvant. As controls two groups were
included, one received a placebo formulation (negative control) and
the other was inoculated with infective DEN-2 virus (positive
control). Thirty days after the third dose, humoral and cellular
immune responses were determined, also was evaluated the
protective capacity of the induced response against a challenge with
DEN-2 virus.
Characterization of the humoral immune response
Two ELISA systems were used, which mainly differed on the
antigen used: domain III-capsid protein or DEN-2 virus. The evalua-
tions showed that all mice from groups immunized with either
aggregated or non-aggregated forms of the chimeric protein devel-
oped a high humoral immune response against both domain III-capsid
and DEN-2 virus, with statistical signiﬁcant differenceswith respect to
the negative control group (Pb0.001) (Fig. 4A and B).
The functionality of these antibodies was further assessed in a
plaque reduction neutralization test. In agreement with the results
from the two ELISA systems described above, the neutralization titers
induced by both formulations of protein domain III-capsid did not
have statistical signiﬁcant differences, and were, additionally, similar
to those generated with the infective virus (positive control group)
(Fig. 4C).
IFN-γ and IL-4 secretion
Culture supernatants of treated splenocytes from immunized
animals of each group were tested by ELISA to measure the
concentration of IFN-γ and IL-4. As shown in Fig. 5A, when the
recombinant protein was used for in vitro stimulation there are higher
levels of IFN-γ secretion in splenocytes from animals immunized with
252 I. Valdés et al. / Virology 394 (2009) 249–258aggregated domain III-capsid (1258.83±340.37 pg/mL) than in those
from animals immunized with the non-aggregated formulation
(651.75±370.5 pg/mL); this difference was statistically signiﬁcant
(Pb0.05). Levels of IFN-γ secreted in splenocytes from animals
immunized with the aggregated form were also higher than those
developed by DEN-2-immune animals (Pb0.05).
A similar outcome was obtained when using the virus for in vitro
stimulation during the measurements of IFN-γ, with higher concen-
trations for the splenocytes from animals immunized with the
aggregated form (570.9±124.33 pg/mL vs. 311.6±130.5 pg/mL for
aggregated vs. non-aggregated, respectively); again, this difference
was statistically signiﬁcant (Pb0.05). In contrast to the previous
experiment, however, DEN-2-immune animals developed the highest
response (837.0±154.6 pg/mL) (Pb0.05) (Fig. 5B).
No IL-4 secretion was detected in any of the assayed groups upon
stimulation with the virus. This suggests the presence of a typical Th1
pattern in the anti-DEN-2 immune response generated by the
immunogens employed in the present study (Fig. 5C).
Given the fact that the aggregated form of the domain III-capsid
protein generated the best levels of IFN-γ secretion, we performed a
second experiment to determine the relative contribution of CD4+
and CD8+ populations to this result. As shown in Fig. 6 and in
agreement with the in vitro virus stimulation experiment, high levels
of IFN-γ were secreted by the splenocytes of mice immunized with
the aggregated forms of the domain III-capsid protein. These levels
suffered a statistically signiﬁcant decrease (Pb0.01) upon depletion of
either CD4+ or CD8+ cells; and a similar result was obtained for the
splenocytes from DEN-2-immune animals (Fig. 6).
Protection assay
One month after the last dose, 10 mice from each group were
inoculated by the i.c. route with a live neuroadapted DEN-2 virus in
order to examine the protection afforded by the different immuno-
gens employed in this study. Fig. 7 shows the mortality data during
the 21 days of post-challenge observation. When administered in
non-aggregated form, the domain III-capsid protein failed to protect
the animals against the neurovirulent challenge, with a survival rate
of only 20%. Interestingly, however, the aggregated domain III-capsid
formulation protected 70% of the animals; this protection was
statistically signiﬁcant when compared to the negative control
group (Pb0.01) but otherwise undistinguishable from the high levels
of protection exhibited by the positive control group.
The effect produced by the in vivo depletion of either CD4+ or CD8+
cells on the protection afforded against DEN-2 virus challenge was also
examined. One month after the last dose, a subgroup of the animals
immunizedwith the aggregated formwas inoculatedwith anti-CD8+ or
anti-CD4+-depleting monoclonal antibodies, followed by a challenge
with a neurovirulent mouse-adapted DEN-2 virus 3 days later. After the
observation period, the survival rates decreased to 0% and 40% in the
CD4+ and CD8+-depleted groups, respectively; these values were
statistically undistinguishable from those of the negative control group
(Fig. 8). The survival rate in the groups of non-depleted mice was not
affected by the inoculation of MAb 2C4, an isotype-matched control
antibody (data not shown). Moreover, the mortality rate in mice fromFig. 4. Humoral immune response in mice immunized with recombinant domain III-
capsid protein. (A) Anti-recombinant antibody response by an ELISA system. The
analysis of data was performed using a Kruskal–Wallis non-parametric test with Dunn's
multiple comparison test. Data represent the geometric mean with 95% conﬁdence
intervals. (B) Antiviral antibody response by a capture ELISA system. The analysis of
data from ELISA was performed using a Tukey's multiple comparison test. Data
represent the geometric mean with 95% conﬁdence intervals. (C) Neutralizing antibody
response by PRNT. The analysis of data was performed using a Tukey's multiple
comparison test. Data represent the mean with 95% conﬁdence intervals, (n=10 per
group).
Fig. 6. Effect of CD8+ and CD4+ cell depletion in splenocytes stimulated with DEN-2
virus, from mice immunized with the aggregated form of domain III-capsid protein.
Undepleted, CD8+-depleted and CD4+-depleted splenocytes were stimulated with
DEN-2 antigen. After 4 days of culture the supernatant of each condition was analyzed
to determine the IFN-γ concentration by ELISA. Data represent mean±SEM. Statistical
analysis was performed using two-way ANOVA with Bonferroni post test (⁎⁎Pb0.01;
⁎⁎⁎Pb0.001) (n=5 per group).
253I. Valdés et al. / Virology 394 (2009) 249–258the placebo group was not affected by CD4+ or CD8+ cell-depletion
(data not shown).
Discussion
Recently our group reported that a semipuriﬁed fraction of the
capsid protein obtained from recombinant E. coli conferred partial
protection in themouse encephalitis model without the induction of a
functional humoral response (Lazo et al., 2007). Since this protein has
been identiﬁed as a target of the antiviral T-cell response (Gagnon et
al., 1996), an involvement of the CMI is the most logical explanation
for this result. On the other hand, we have also demonstrated that
fusion proteins containing the P64k antigen and domain III of the
Envelope protein from dengue virus can induce a functional antibody
response, as measured by the induction of neutralizing antibodies and
protection in mice and monkeys (Hermida et al., 2004a, 2004b, 2006;
Bernardo et al., 2008; Valdés et al., 2009). Given that domain III also
seems to mediate the interaction of dengue virus with its putative
receptor in the target cells (Rey et al., 1995; Chen et al., 1996; Huerta
et al., 2008), we decided to obtain a novel domain III-capsid chimeric
protein as a molecule potentially able to induce both a humoral
immune response and cell-mediated immunity, using the N-terminus
of the capsid protein as the fusion site for the domain III moiety.
The chimeric product was successfully obtained in E. coli as a
soluble protein in rupture supernatants, as was earlier the case for the
capsid gene product alone (Lazo et al., 2007). The solubility of the
fusion protein suggests that the molecule is properly folded, which
constitutes an important condition for preserving the antigenicity of
the domain III fragment. Proper folding of the domain III portion was
also suggested by the presence of its intramolecular disulphide bond,
as revealed the analysis by mass spectrometry. This bond has beenFig. 5. IFN-γ and IL-4 secretion upon in vitro stimulation measured by ELISA. (A)
Concentration of IFN-γ in culture supernatants of recombinant protein-stimulated
splenocytes. (B) Concentration of IFN-γ in culture supernatants of DEN-2-stimulated
splenocytes. (C) Concentration of IL-4 in culture supernatants of DEN-2-stimulated
splenocytes by ELISA. Data represent mean±SEM. The analysis of data from ELISA was
assessed using a Tukey's multiple comparison test (⁎Pb0.05; ⁎⁎Pb0.01; ⁎⁎⁎Pb0.001)
(n=5 per group).
Fig. 7. Protection study. Groups of mice were immunized either with placebo, the two forms of domain III-capsid protein or infective DEN-2 virus. A month after the last
immunization, animals were challenged intracranially with 50 LD50 of lethal DEN-2 virus. Data from protection assay were analyzed by the log-rank test, (⁎Pb0.05; ⁎⁎Pb0.01;
⁎⁎⁎Pb0.001) (n=10 per group).
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antibodies, which typically recognize conformational epitopes
(Huerta et al., 2008). In agreement with this fact, DEN-speciﬁc sera
from different sources showed a high degree of reactivity with the
fusion protein.
Domain III-capsid was obtained with a purity of 65% after
puriﬁcation process and the low molecular weight protein con-
taminants observed during SDS-PAGE analysis were degradation
products as revealed by their reactivity with MAb 8H8. The same
puriﬁcation process was performed from an E. coli transformed with
the capsid gene alone, and contaminant bands were not visualized
(Fig. 2C, line 7), constituting an additional evidence of the lack of
substantial quantities of E. coli contaminants. The degradation
phenomenon was previously observed for chimeric P64k-domain
III proteins, in which the viral sequence was inserted within the
N-terminal domain of the carrier protein (Zulueta et al., 2003).
The partially puriﬁed protein was subjected to an in vitro
particulation process employing DNA oligonucleotides to obtain an
aggregated form with improved immunogenicity. This process has
been previously used for the in vitro assembly of recombinant capsid
protein, obtaining nucleocapsid-like particles (NLPs) with an approx-
imate diameter of ∼30 nm (López et al., 2009). In the present case,
however, the particulation protocol yielded highly aggregated species
as revealed by electron microscopy, which were heterogeneous bothFig. 8. Effect of in vivo CD8+ and CD4+ cell depletion in the protection rate of the group
immunized with the aggregated form of domain III-capsid protein. Brieﬂy, one month
after the last dose, the group of animals immunized with the aggregated form of
domain III-capsid was divided in four subgroups. Two subgroups were inoculated with
the anti-CD8+ or the anti-CD4+-depleting MAbs (CD4+ and CD8+ depleted groups,
respectively). Another subgroup received PBS (non-depleted). As isotype-matched
control antibody administration, an additional subgroup was inoculated with the MAb
2C4 (data not shown). In turn, the remaining animals (n=10 per group) were injected
intracranially with lethal DEN-2 containing 50 LD50. Mice were observed daily for
21 days and deaths were recorded. Statistical analysis was performed by the log-rank
test, (⁎⁎Pb0.01; ⁎⁎⁎Pb0.001).in size and morphology. However this result allows to afﬁrm that the
capsid protein is able to form particles even carrying large fragments
of heterologous sequences in its structure (~146 amino acids).
The immunological evaluation was the last stage of the present
work. Two different formulations of the domain III-capsid protein,
aggregated and non-aggregated, were inoculated in mice and the
immune response induced was characterized. The analysis of the
humoral immune response revealed the induction of antiviral
antibodies similar to those elicited by infective DEN-2 virus. These
antibodies were able to neutralize the virus in vitro, further
conﬁrming the preservation of the antigenicity of domain III in the
chimeric protein. Interestingly, the humoral immune responses
induced by the two formulations were undistinguishable, indicating
that the conformation of domain III did not change signiﬁcantly even
after aggregation. These results constitute an additional evidence of
the capacity of domain III (as a fusion protein) to induce neutralizing
antibodies in mice as reported by several groups (Simmons et al.,
1998; Hermida et al., 2004a, 2004b).
On the other hand, the fact that spleen cells from immunized mice
produced high levels of IFN-γ upon in vitro stimulation with DEN-2
virus revealed that the domain III-capsid antigen was also capable of
inducing cell-mediated immunity. In contrast to the results obtained
for the humoral immune response, however, the splenocytes of mice
immunized with the aggregated form showed higher levels of IFN-γ
secretion than those from the non-aggregated group. These results are
relevant for the potential use of this antigen as a vaccine candidate,
since IFN-γ constitutes a mediator of the cellular immune response
and has been shown to play a key role in antiviral activity against
dengue (Shresta et al., 2004; Yauch et al., 2009).
The results of the assay for protection against a homologous viral
challenge showed that the immunization with the aggregated form of
the chimeric domain III-capsid protein induced a signiﬁcant level of
protection, which was otherwise undetectable for the non-aggregated
formulation. These results mirror the outcome of the in vitro assays for
IFN-γ secretion described above, suggesting that the most important
element for the induction of a functional immune response in terms of
CMI and protection was the addition of oligonucleotides into the
partially puriﬁed fraction of the protein. Whether the enhanced
functionality of this formulation is related to the physical aggregation
of the molecule or to the presence of oligonucleotides within the
aggregates remains an unanswered question. It is known that
particles or aggregated protein species may be more efﬁciently
cross-presented than soluble antigens (Ackerman et al., 2006), but on
the other hand, there are also several studies showing that
oligonucleotides can have adjuvant capacity for the induction of
cell-mediated immunity to target antigens (Chaung, 2006). Although
the oligonucleotides employed in the present study were a mixture of
several unspeciﬁc 50 b sequences whose adjuvanticity has not been
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encapsulating the oligonucleotides, protecting them against nucleo-
lytic degradation and favoring entry into the APC due to its aggregated
nature. Once inside the cells, the oligonucleotides can interact with
intracellular receptors such as TLR-9 and trigger the stimulation
process (Takeshita et al., 2001).
Finally, the contribution of both CD4+ andCD8+ cell populations to
the in vitro IFN-γ secretion results as well as the protection assays,
support a functional role for the cell-mediated response induced after
immunization, specially in the case of the aggregated form of the
chimeric protein. Virus-like particles from several viruses have been
shown to induce dendritic cell maturation and secretion of cytokines
such as IFN-γ that stimulate CD4+ and CD8+ T cells (Chung et al.,
2008). Since subsets of CD4+ T-cells capable of lysing infected cells
have been previously characterized forﬂaviviral diseases (Aihara et al.,
1998), including dengue (Green et al., 1993; Berrios et al., 1996;
Gagnon et al., 1996, 1999), in the present study this cell population
could be directly involved in protecting against the disease. In
addition, its role as “helper” should be considered. On the other
hand, CD8+ cells are a known source of INF-γ secretion, as shown
consistently by the in vitro assay. Although in the in vivo depletion
experiment the statistical signiﬁcance between non-depleted and
CD8+-depleted groups was not reached, the percentages obtained in
the latter did not exhibit statistical differences with respect to those
corresponding to the placebo group, indicating no relevance of the
protection levels obtained. It means that CD8+ cells can inﬂuence in
the protection of the non-depleted group. Based on the cross-
presentation phenomenon deeply described for aggregated antigens,
we consider that aggregated form of the domain III-capsid protein was
processed by the MHC I pathway and the CD8+ epitopes were properly
presented, inducing a functional cytotoxic T lymphocyte response.
Finally, it is important to emphasize that the humoral response
was not relevant for the much higher level of protection conferred by
immunization with aggregated domain III-capsid in the mousemodel,
since the amounts of antiviral and neutralizing antibodies induced by
both formulations were similar. This ﬁnding is consistent with the
previous report in which the semipuriﬁed capsid protein was able to
induce partial protection in mice without generating antiviral
antibodies (Lazo et al., 2007) and therefore, constitute an additional
evidence of the role of CMI against DEN virus in the mouse model.
Nevertheless, the immunological relevance of the antibodies, impor-
tant arm of the immune system, should not be ignored since
experiments in non-human primates and humans could raise
different results.
It is important to highlight that a future dengue vaccine candidate
based on the present molecule (domain III-capsid), presumably
should contain the mixture of the four antigens corresponding to
serotypes 1, 2, 3 and 4 since domain III region, as a fusion protein,
induces serotype-speciﬁc antibodies (Izquierdo et al., 2008). We also
have recently demonstrated that capsid protein from DEN-2 induces
protection and IFN-γ secretion mainly against the homologous
dengue serotype (data pending publication).
We can conclude than the novel domain III-capsid chimeric
protein, as a recombinant construct produced in E. coli and highly
aggregated by the addition of oligonucleotides, induced a functional
humoral response and CMI against DEN-2 virus and conferred a
signiﬁcant protection in mice.
Material and methods
Bacterial strain, antibodies and recombinant proteins
E. coli XL1-Blue [F' ::Tn10 proA+B+lacIq Δ(lacZ) M15/recA1 en-
dA1gyrA96(NaIr) thi hsdR17 (r−k m+k ) supE44 relA1 lac] was used
for the propagation of plasmids and for the expression of the
recombinant gene (Bullock et al., 1987).The polyclonal hyperimmune ascitic ﬂuid (HMAF) against DEN-2
virus, the monoclonal antibodies (MAb) 4G2 and 8H8 used in this
study were kindly provided by the Department of Virology, “Pedro
Kourí” Tropical Medicine Institute, Cuba. The MAb 8H8 is a mono-
clonal antibody type IgG1, which recognizes the native capsid protein
from DEN-2 virus. It was generated after mice inoculation with DEN-2
virus (A15-strain) (Pupo Antunez et al., 1997). The MAb 4G2 was
employed as a positive control for the Plaque reduction neutralization
test. Its neutralizing capacity has been previously reported, which
recognizes the ﬂavivirus E protein (Kaufman et al., 1987).
The depleting antibodies employed in the in vivo depletion
experiment were kindly provided by Dr. J. V. Gavilondo, Pharmaceu-
tical Department, CIGB.
The MAb 2C4 used in the in vivo depletion, as isotype-matched
control antibody experiment was kindly provided by Dr. C. Duarte,
Vaccine Division, CIGB.
The monoclonal antibody 448 (anti-P64k), which recognizes an
epitope at the N-terminus of the P64k protein (Silva et al., 1992), was
kindly provided by Meningo Department on Vaccine Division, CIGB.
Recombinant proteins capsid and PD5 (P64k-domain III of DEN-2
virus), acting as controls, were previously obtained by our groups as
described by Lazo et al., 2007 and Zulueta et al., 2003, respectively.
Viral antigens
An inactivated preparation from suckling mice brain infected with
DEN-2 virus strain New Guinea C (highly passaged in mice) was used
as antigen for antibody detection (Churdboonchart et al., 1991). A
preparation obtained from brain of non-inoculated mice was used as
negative control.
For animal immunization and virus challenge, a preparation of
infective DEN-2 virus (105 pfu/mL) was employed. It was obtained by
homogenization in RPMI 1640 medium (Sigma Aldrich, Ayrshire KA,
UK) of suckling mice brain infected with DEN-2 virus strain A15
(isolated in Cuba, 1981).
For the neutralization assay, cell-culture supernatant harvested
from Vero cells infected with the DEN-2 strain SB8553 (kindly
provided by Dr. M. J. Cardosa, University Sarawak,Malaysia) was used.
A concentrated preparation of virus (DEN-2 antigen) was used for
the in vitro stimulation of mouse splenocytes. Supernatant from Vero
cells infected with 106 pfu/mL of SB8553 DEN-2 viral strain was
concentrated by centrifugation at 80,000×g , 4 h at 4 °C. The pellet
containing the virus was resuspended in phosphate-buffered saline
(PBS) (Gibco, Paisley, UK). Amock preparationwas similarly prepared
from the supernatant of uninfected Vero cells.
Construction of the expression plasmid pDomIII-Capsid2
The region corresponding to the domain III of the E protein of DEN-2
virus (strain Jamaica) was ampliﬁed by reverse transcriptase-polymer-
ase chain reaction (RT-PCR)using theupstream21-residue oligonucleo-
tide 5′CTTGGATCCAGGCTGAGAATG3′ and the downstream 33-residue
oligonucleotide 5′TGTGGATCCTCCTCCTAGGCTTCCAAAATCCCA3′ as
primers.
Brieﬂy, the RT-PCR ampliﬁcation was performed under the
following conditions: 30 cycles of 95 °C for 1 min, 54 °C for 1 min
and 72 °C for 30 sec. The reaction components were: 5 ng of viral RNA;
50 pmol of primers; 200 μM of each deoxynucleotide triphosphates
(dNTPs); PCR buffer (50 mM KCl, 10 mM Tris-HCl pH 8.5, 1.5 mM
MgCl2); 0.01% (v/v) of gelatin and 5 mM dithiotreitol. The reaction
was performed at a ﬁnal volume of 100 μL using 2.5 units per reaction
of Thermus aquaticus DNA polymerase (Boehringer, Germany) and 10
units of reverse transcriptase puriﬁed from avian myeloblastosis virus
(RT AMV) (Boehringer, Germany).
The ampliﬁed fragment was cloned into the pGEM-T vector
(Promega, USA). Positive clones were tested by restriction analysis
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(Sanger et al., 1977). The band codifying for the domain III was obtain
using the enzyme BamHI and was cloned into the plasmid pDC-2,
previously digested BamHI and treated with enzyme CIP. The pDC-2
plasmidwaspreviously obtainedbyLazoet al. (2007)and it contains the
recombinant capsid protein in the pQE30 vector. The positive clones
were tested by restriction analysis and sequence. The selected plasmid
was named pDomIII-Capsid2 (Fig. 1). All the plasmidswere constructed
by using standard DNA techniques (Sambrook et al., 1989).
Expression of the chimeric domain III-capsid protein
E. coli strain XL1-Blue was transformed with pDomIII-Capsid2 or
pDC-2 plasmids. Transformed colonies of each construct were
inoculated onto 5 mL of Luria Bertani cultures containing ampicillin
(50 μg/mL) (LBA), and grown during 12 h. After that the cultures was
refreshing onto 500 mL cultures of LBA and were grown in a shaker at
37 °C to obtain optical density of 0.6. For promoter induction,
isopropyl-B-d-thiogalactopyranoside (IPTG) was added to a ﬁnal
concentration of 1 mM. Bacteria were harvested by centrifugation at
3,000×g for 15 min at 4 °C and washed once with 10 mM Tris-HCl,
6 mM EDTA, pH 8 (TE buffer). Then, cellular biomass was resuspended
in 30mL of TE buffer and cells were disrupted in French Press (Othake,
Japan) at 1500 kg/cm2, with two passes on 4 °C. After, cell-disruption
was centrifuged at 20,000×g for 20 min at 4 °C; the disruption
supernatantwas collected and stored at-70 °C for further experiments.
Puriﬁcation of the recombinant domain III-capsid protein
The supernatant from disruption in TE buffer was exchanged to
10 mM Tris-HCl, 6 mM EDTA, 7 M Urea, Tween 0.5%, pH 8 using
Sephadex G-25 ﬁne (Pharmacia, Sweden). The supernatant was gently
shaked during 12 h at 4 °C before the application onto the SP-
Sepharose FF resin (Pharmacia, Sweden), previously equilibrated with
the same buffer. The column was washed with 30 mM Diethanola-
mine (DEA), 6 mM EDTA, 7 M Urea, Tween 0.5%, 350 mM NaCl, pH
10.3 (washed buffer), to eliminate contaminants. Then, the recombi-
nant protein was eluted using 30 mM DEA, 6 mM EDTA, 7 M Urea,
Tween 0.5%, 750 mM NaCl, pH 10.3 (elution buffer). Finally the
protein was refolded using Sephadex G-25 ﬁne to TE buffer and was
stored at−20 °C until next experiments.
Western blotting
Proteins were transferred from the acrylamide gel onto a Hybond-
C membrane as described (Lazo et al., 2007).
Mass spectrometry
Samples from the semipuriﬁed domain III-capsid protein were
digested with trypsin (Promega) and Lysil-endopeptidase (LEP, Wako).
Both digests were carried out at 37 °C during 12 h using an enzyme:
substratemass ratio 1:50. Peptides derived were trapped in ZipTips C18
(Millipore, USA)microcolumns, eluted and applied onto a gold-covered
borosilicate capillary (Micromass, UK) for mass spectrometry analysis.
Mass spectra were acquired on a QTOF-2TM (Micromass, UK)
hybrid instrument equipped with a nanoESI ion source. Capillary and
cone voltages were 900 V and 35 V, respectively. Source block
temperature was 80 °C. The instrument was calibrated with sodium
and cesium iodide from 50 to 2000 Da. The software for data
processing was MassLynx 3.5 (Micromass, UK).
In vitro assembly reaction and electron microscopy
The semipuriﬁed domain III-capsid protein was subjected to an in
vitro assembly procedure as previously described with few modiﬁca-tions (López et al., 2009). Brieﬂy, 20 μg of the recombinant domain III-
capsid protein was incubated with single-stranded DNA oligonucleo-
tides (random sequences) at a protein:nucleic acid molar ratio of 3:1
in TE buffer. The reaction mixture was incubated for 30 min at 30 °C
and ﬁnally stored at 4 °C. Particles were visualized by electron
microscopy.
For microscopy analysis, samples were placed on a freshly glow-
discharged, 400-mesh copper grid coated with Formvar and carbon.
Following 2 min of sample absorption and extensive washing with
water, uranyl acetate stain was applied. After 4 min of staining, grids
were wick dried with Whatman no. 1 ﬁlter paper and allowed to air
dry for 20 min. Samples were then viewed on a JEOL/JEM 2000 EX
electron microscope (JEOL, Japan). Three different pictures were
analyzed by the ImageJ software (version 1.33) to determine the
number of particles and their sizes.
Immunizations and protection assays
Groups of female 5- to 6 week-old Balb/c (Bc, H-2d) mice
(CENPALAB, Cuba) were injected by intraperitoneal (i.p.) route on
days 0, 15, and 30. All formulations had a volume of 150 μL and were
prepared with aluminum hydroxide (alum) (Alhydrogel) (Brenntag
Biosector, Denmark) as adjuvant at a ﬁnal concentration of 1.44 mg/
mL. Four groups were included in the study:
Group 1 (Placebo): each mouse was inoculated with 3 μg of the
oligonucleotide in TE buffer. n=20.
Group 2: each mouse was inoculated with 22.5 μg of non-
aggregated domain III-capsid protein. n=20.
Group 3: each mouse was inoculated with 22.5 μg of aggregated
domain III-capsid protein. n= 58.
Group 4 (positive control): Each mouse was inoculated with only
one dose (0.5 mL) at day 30 of the preparation of DEN-2 (strain
A15) as described above (subsection Viral antigens), without
adjuvant. n=20.
Ten mice from each group were bled and splenectomized a month
after the last dose and sera were collected for further immunological
analysis.
Additionally, 1 month after the last dose, 48 animals from Group 3,
which were inoculated with 22.5 μg of aggregated domain III-capsid
protein, were divided in four subgroups (A. B, C and D). The subgroups
A and Bwere inoculated by i.p routewith a single dose of 100 μg of the
highly puriﬁed anti-CD8+ (clone YTS 169.4) and the anti-CD4+-
depleting (clone YTS 191.1) MAbs, respectively. Subgroup C received
PBS. As isotype-matched control antibody administration, subgroup D
was inoculated with the MAb 2C4, speciﬁc for the V3 region of the
gp120 protein of the HIV-1 MN isolate. Three days after the
inoculations two animals of each subgroup were splenectomized
and cell-speciﬁc depletion was conﬁrmed by ﬂow cytometry. More
than 94% of the CD4+ or CD8+ cells were depleted in animals
inoculated with the speciﬁc MAb (data not shown).
Finally, one month after the last dose, the remaining animals from
each group were injected intracranially (i.c) with 20 μL of a
suspension of DEN-2 (strain A15) virus-infected suckling mouse
brain containing 50 median lethal doses (LD50). Mice were observed
daily for 21 days and deaths were recorded. Themaintenance and care
of experimental animals used in this research complied with the
Cuban Institute of Health Guidelines for the humane use of laboratory
animals.
Anti-recombinant protein antibodies by enzyme linked immunosorbent
assay
The antibody response to the recombinant domain III-capsid
protein was measured by enzyme-linked immunosorbent assay
257I. Valdés et al. / Virology 394 (2009) 249–258(ELISA). Brieﬂy, ﬂat-bottomed 96-well plates (Costar, USA) were
coated with 5 μg/mL of domain III-capsid or capsid protein for 2 h at
37 °C in coating buffer (0.16% Na2CO3, 0.29% NaHCO3, pH 9.5). As
negative control the plates were coated with 5 μg/mL of negative
process of puriﬁcation, corresponding to cells transformed with the
pQE30 plasmid. Three washes with PBS-T were completed after each
step of the ELISA. Plates were blocked with 2% bovine serum albumin
(BSA), 1 h at 37 °C. Anti-DEN sera samples of three different species
(human, monkey and mouse) were serially diluted and incubated 1 h
at 37 °C with each protein preparation. Anti-monkey, anti-human or
anti-mouse IgG-peroxidase conjugate (Sigma, USA) were added and
the plates were incubated for 1 h at 37 °C. After washing, 0.04%
substrate solution (O-phenilendiamine in buffer 2% Na2HPO4, 1% citric
acid, and 30% H2O2, pH 5.0) was added. Plates were kept 30 min at
25 °C and the reaction was stopped with 12.5% H2SO4. Absorbance at
492 nm was read in a microplate reader (SensIdent Scan; Merck,
Germany). The positive cut-off value was taken as twice the
absorbance value of the negative control.
Antiviral antibodies by enzyme linked immunosorbent assay
The anti-DEN IgG antibodies stimulated by immunization were
monitored by an ELISA system as previously described by Lazo et al.
(2007). Absorbance was read at 492 nm in a microplate reader
(SensIdent Scan; Merck, Germany). Titers were deﬁned as the dilution
of serum giving twice the absorbance value of the negative control
serum.
Plaque reduction neutralization test
Neutralizing antibody titers were measured by plaque reduction
neutralization test (PRNT) in BHK-21 cells as previously described
(Morens et al., 1985). The strain SB8553 was used in this test. The
neutralizing antibody titer was identiﬁed as the highest serum
dilution that reduced the number of virus plaques by 50%. The MAb
4G2 was used as positive control, which recognizes the ﬂavivirus E
protein (Kaufman et al., 1987).
Cell culture and viral stimulation
Spleen cells were obtained in aseptic conditions and erythrocytes
were lysated by adding NH4Cl 0.83% solution. Cells were washed twice
with PBS-2% Fetal Bovine Serum (FBS) (PAA Laboratories, Ontario,
Canada) and resuspended at 2×106 cells/mL in RPMI-1640 medium
(Sigma Aldrich) supplemented with 100 U/mL penicillin, 100 μg/mL
streptomycin (Gibco, UK), 2 mM glutamine (Gibco, UK), 5×10−5 M 2-
mercaptoethanol (Sigma St. Louis, MO) and 5% FBS. Finally 2×105 cells/
well were cultured in 96-well round bottom plates with the antigens
(103 pfu of DEN-2 antigen ormockpreparation). Concanavalin A (ConA)
(Sigma St. Louis, MO) was used as a positive control. In all the
experiments three wells were plated for each antigen. After 4 days of
culture, culture supernatants were collected and stored at-20 °C.
Cytokine detection
The culture supernatants of splenocytes previously stimulated
with each antigen were analyzed in duplicate to determine the IFN-γ
concentration by ELISA using MAbs pairs (Mabtech (INF-γ; Nacía,
Sweden). ELISA protocol recommended by manufacturers was used
with slight modiﬁcations. The lower limit of detection of cytokine was
4 pg/mL.
In vitro cells depletion and ﬂow cytometry analysis
For CD4+ or CD8+ cells depletion, splenocytes at 5x106 cells/mL in
PBS were incubated 30 min at 37 °C with 100 μg of highly puriﬁedanti-CD8+-depleting or anti-CD4+-depleting MAbs, respectively and
rabbit complement (Cedarlane, Ontario, Canada). Later, the cells were
washed twice with PBS-2% FBS and cell-speciﬁc depletion was
conﬁrmed by ﬂow cytometry (data not shown).
For cell-speciﬁc depletion analysis, 1x106 splenocytes in PBS were
incubated 30 min at 4 °C with anti CD8-FITC antibody (Serotec Ltd,
UK) and anti CD4-APC antibody (Serotec Ltd, UK). Samples were
analyzed in duplicate in PasIII ﬂow cytometer (Partec GmbH,
Germany). Dead cells were excluded by PI incorporation. The gates
used in the sample acquisition were saved and analyzed by the
WinMDI software version 2.8 (Purdue University, WL, USA). The
percentage of CD4+ or CD8+ cells was determined by gating on the
positive lineages of the CD4+ or CD8+ subsets.
Statistical analysis
Direct or transformed (Log10) data that passed the normality test
(Kolmogorov–Smirnov or D'Agostino and Pearson omnibus normality
test) and showed variance homogeneity (Bartlett's test) were
analyzed by ANOVA parametric tests. Data that not fulﬁll normality
and /or variance homogeneity test, even after transformations were
analyzed by the nonparametric. Grouped analysis was performed by
the two-way ANOVA with Bonferroni post test. Data from protection
assay were analyzed by the log-rank test. In all cases, the GraphPad
Prism version 5.00 for Windows, GraphPad Software, San Diego
California USA, hhtp://www.graphpad.com was employed.
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